Background: Nonalcoholic fatty liver disease (NAFLD) is the most common cause of pediatric liver disease. Its prevalence is related to the growing epidemic in childhood obesity during the past decades. At present, NAFLD and nonalcoholic steatohepatitis (NASH) are increasingly recognized worldwide. In spite of alarming trend in the epidemiology in pediatric field and growing risk of end stage liver disease, there is no significant advance in its diagnosis and treatment. Aim: To provide a detailed review for diagnosis and management of NAFLD and NASH. Methods: By using Pubmed to find review articles and relevant research. Results: The prevalence ranges from at least 3% in children overall to about 50% in obese children. The noninvasive biomarkers can be used to identify NAFLD/NASH patients. Diagnostic criteria based on biochemical and immunological indicators in the high-risk group of children could prevent about half of cases from receiving an invasive test. The pharmacological and surgical interventions have shown a growing role in pediatric NAFLD. Novel treatment modalities, such as probiotics, have hardly been studied. Conclusion: Early diagnosis by using noninvasive screening methods in high-risk groups is the most effective strategy against the NAFLD. The biology of early growth and development, including hepatic metabolism, may hold the key to pediatric NAFLD. Prevention of overweight children and childhood obesity is undoubtedly the best strategy for treating NAFLD.
Introduction
Nonalcoholic fatty liver disease (NAFLD) is characterized by the accumulation of triglyceride (TG) in hepatocytes. NAFLD ranges from fat in the liverFsimple steatosis, fat with inflammation and/or fibrosisFsteatohepatitis/NASH to advanced fibrosis and cirrhosis when fat may no longer be present. Steatosis is either single large droplets that displace the cytoplasmic contents and the nucleus (that is, macrovesicular) or as smaller, well-circumscribed droplets admixed with cytoplasmic contents (microvesicular). 1 The liver damage consistent with steatohepatitis was reported for the first time, in 1950 in obese individuals. 2 The term NASH (nonalcoholic steatohepatitis) was explained half a century ago by Ludwig. 3 The first cases of pediatric NASH were reported 3 years later. 4 Considering histological variances exist between adult and pediatric fatty liver, extrapolation of adult data may lead to erroneous conclusions. 1, 5, 6 Epidemiology: incidence
Fatty liver is the most common liver abnormality in children aged 2-19 years. 5, 6 However, the true prevalence of NAFLD and NASH is unknown given that the disease's definition and modalities used for diagnosis are not standardized. 7 Most studies of the prevalence of fatty liver in children have been restricted to the use of indirect measures, such as blood tests or ultrasound, to predict a histological outcome.
8 Table 1 shows some epidemiological study results. Two studies in the United States, 9,10 one in Korea 11 and two other studies in Italy 12, 13 used aminotransferase elevation as a surrogate marker of fatty liver disease. This was ideally used in conjunction with negative markers for other types of liver diseases. Other markers, such as the insulin resistance (IR) index, could have a role in screening.
Measurement of abdominal subcutaneous fat thickness by ultrasonography could be a good estimate for liver involvement, especially in obese subjects. [19] [20] [21] [22] [23] Population-based approaches by this method, suggests an overall prevalence of at least 3% for suspected fatty liver disease among children and adolescents in the United States and Asia. 9, 17 The histology of the liver, the most important criterion for diagnosis is usually not being used for screening. Data from autopsy records shows the prevalence of NASH about 6.27% in adults. 24 According to retrospective study in autopsy finding, fatty liver was present in about 13% of children and adolescents. Histologocal evidences of steatohepatitis have been shown in 23% of this group. The presence of macrovesicular hepatic steatosis in 1 of every 10 children has important consequences for the long-term health of youths. 17 A cross-sectional study of liver biopsy during gastric bypass surgery was performed in morbidly obese adolescents. NAFLD was very prevalent in this group (33%), and histopathological finding in 20% of subjects was compatible with NASH. 25 NASH had case histories published from North America, Europe, Australia and Asia. 9, 13, 16, 18 About two-thirds of obese adults and half of obese children may have fatty liver. 17, 19, 21 When compared with their normal counterparts, overweight and obese adolescents had 4.14 and 5.98 times the risk of having NAFLD. 22 In reported clinical series of pediatric NAFLD, the mean age was between 11 and 13 years. 8 The prevalence of fatty liver rises with increasing age. 10 After controlling for gender, race, and ethnicity, its prevalence increased with age ranging from 0.7% for ages 2-4 years up to 17.3% for ages of 15-19. 8,19 The pediatric fatty liver disease has shown a male predominance on the basis of pathology 9, 26 and higher abnormal alanine transaminase (ALT) (males: females, 44-7%). 9 Biopsy-proven NAFLD has a ratio of 2.2:1 in boys to girls on the basis of linking of clinical cases from four different continents. 15, 17 Hispanic ethnicity, Asian race has shown more prevalence of fatty liver. Black children, even obese, are much less likely to have NAFLD than white children. However, these studies could not contradict race-based selection bias. [5] [6] [7] 9, 17 Prevalence of obesity and its related comorbidity, especially NAFLD, has been increased notably in last decades. Epidemiological studies are the fundamental part of research for diagnosis and management of such a chronic disease because of profound decrease in the quality of life.
However, there are emerging data that show significant differences do exist between adult and children NAFLD. Therefore, prevalence studies in the pediatric field are imperative to delineate the pathophysiology of NAFLD in children and adolescents, identification of high-risk group and establishment of screening criteria for NAFLD-NASH.
Natural history
The disease presents itself from asymptomatic elevated liver enzyme levels to cirrhosis with complications of liver failure and hepatocellular carcinoma. 16, 27 Clinical studies have reported fibrosis in 53-100% of liver biopsies from children with NAFLD. There are several cases presented with cirrhosis. 15, 16, 27 First long-term follow-up study in pediatric fatty liver describe the overall survival of children with NAFLD up to 20 years. Pediatric fatty liver has shown a progressive potential. 1, 5 It is associated with a significantly shorter long-term survival in comparison with the expected survival of the normal group. On the basis of this study, children with NAFLD had about a 14-fold higher risk of mortality or requiring liver transplantation than the general population of the same age and sex. 5, 6 Fatty liver may develop very early in life parallel to an increasing prevalence of obesity and metabolic syndrome. The cases reported were as young as 2-years of age. However, most of the cases were diagnosed in the second decade of life. 5, 8 The presence and severity of fibrosis were consistently associated with a higher body mass index or larger waist circumference 15, 21, 26 and had some relation to older age, higher levels of aspartate aminotransferase and insulin. 27, 29 These 'fibrosis predictors' have ranged from 10 to 25% of elevated ALT in obese adolescence to 52-77% bright liver, in sonography, in different studies in several countries. 10, 13, 19, 30 Fatty liver patients are at risk of developing diabetes or impaired glucose tolerance in long term. 5, 20, 24 Accordingly, NASH patients display elevated gamma-glutamyltransferase levels, high-density lipoprotein cholesterol below the fifth percentile for their age and sex. 30, 31 Some of the characteristics of pediatric NAFLD may partly be because of the occurrence of hepatic metabolic derangements, typical of NAFLD, during periods of active growth (infancy, mid-childhood and puberty). 6, 8, 26 Unlike adults, the majority of children have portal-based injuries on liver biopsies. 5, 28 The importance of pediatric NAFLD extends beyond the highly probable increased burden of serious chronic liver disease as children with NAFLD reach adulthood. 5, 6 Target group for secondary prevention on the basis of natural history and the youngest age of diagnosis is children aged from 5 to 9 years. 5 Overall, natural history of fatty liver disease is compatible with a progressive disease accompanied with several metabolic derangements. This evolution could have occurred over a relatively short period and highlight the importance of the 'predictors of severity'. Obesity, higher waist circumference and elevated level of liver enzyme and insulin resistance (IR) tests have the potential to be used for identification of the high-risk group. Nevertheless, further studies are needed to determine these predictors.
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Mechanisms
The pathogenesis of fatty liver in children and progression to NASH is not fully understood. 6 Nonetheless, there is some principle theoretical points, describing the pathophysiological mechanism of disease. In addition to a background of unhealthy nutrition and sedentary lifestyle, accumulation of hepatic fat is closely linked to IR, the metabolic syndrome and subsequently to increase hepatic glucose production and changes in lipogenesis in the liver. Most of the time, the process of fatty liver is limited to this stage and remains innocuous. In some cases, this disease has shown a progressive course. The 'two-hit model' tries to explain the role of oxidative stress, mitochondrial dysfunction, inflammatory cytokines, hormonal disturbances as the second hit in pathogenesis of NASH. 6, 26, 28 Insulin resistance Obesity and type II diabetes are associated with hyperinsulinemia and IR, which may inhibit fatty acid oxidation and increase the presentation of fatty acids to the liver. 19 Markers of IR, are present in both obese and normal weight NAFLD patients. 32, 33 Hyperinsulinemia is a principal contributor to the development of fatty liver in childhood obesity. 18, 26 The severity of hyperinsulinemia is predictive of the degree of steatosis, inflammation and fibrosis. Homeostasis model assessment of IR (HOMA-IR) can differentiate between the simple steatosis and the NASH group. 21, 27, 28 In a retrospective evaluation of biopsy-proven pediatric NAFLD, fasting hyperinsulinemia was present in 75% of subjects. About 95% of the subjects met the criteria for IR (HOMA-IR). 27 In another study in Italy, 62% of children with fatty liver have shown HOMA-IR 42. 33 However, there are cases in which a normal body mass index, normal glucose tolerance and a normal lipid profile may still meet criteria for IR. The IR and NAFLD may precede the development of obesity, overt diabetes and dyslipidemia later in life. 26, 27, 33 Although several studies have shown the association of altered insulin sensitivity with NAFLD in children; they are unable to show specific insulin action on different organs. 29, 32, 34 There is some strong evidence that indicate both low-birth weight and catch-up-growth in infants seem to correlate with some aspects of a later metabolic syndrome including IR, type 2 diabetes, dyslipidemia and NAFLD. 35 Body-fat distribution changes, decrease in insulin sensitivity and increase in the sex hormones occurred during the normal course of puberty. All of which may predispose the subject to the development of hepatic steatosis. In children who enter puberty with excess fat and/or an underlying genetic predisposition to IR, hormonal changes that occur as a normal part of growth and development may 'tip the scales' toward the onset of fatty liver disease. 6, 36 In summary, IR is a principal part of the chain process of pediatric fatty liver. There is also some evidence of IR because of the metabolic and endocrine changes of growth spurts during infancy and puberty. Children being evaluated for NAFLD should therefore, be screened for IR, which is nearly universal and correlates with liver histology.
Metabolic syndrome (MS)
NAFLD is considered to be the liver component of the MS. 6, 37 A high proportion of visceral fat and a comparably low amount of fat in subcutaneous compartment in adolescents, even in not necessarily the most severely obese, is accompanied by severe metabolic complications of obesity. This group has a high risk of having the MS.
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A large case-control study has shown that overweight and obese children with MS had greater odds of having NAFLD than overweight and obese children without a MS. 39 Increasing prevalence of MS and higher occurrence of MS components were strongly correlated with the development of NAFLD and severity of IR.
premorbid cardiovascular state. 1, 6, 32 Other studies have indicated an association between liver disease and raised transaminases to the MS only in severe obesity, suggesting that NAFLD might be a secondary phenomenon. 5, 26 Fatty liver is now recognized as an independent marker for increased cardiovascular risk known collectively as the MS. New biomarkers relating to IR and other obesity related metabolic changes might provide a clear basis for defining MS and also NAFLD in children.
Change in lipogenesis
In a healthy state, elevated lipid concentrations in the liver lead to increased very-low density lipoprotein production and secretion. However, in NAFLD/NASH, this increase in fat export by very-low density lipoprotein may be impaired or insufficient to be able to prevent fatty liver. 41 De novo lipogenesis was elevated in the fasting stateF accounting for 25% of liver very-low density lipoprotein compared with 5% in healthy individuals, and failing to increase postprandially. 42 A recent study by Donnelly et al. 43 using a multiple-stableisotope labeling approach, showed that in NAFLD patients plasma free fatty acids were the primary contributor to the liver triacylglycerol content in the fasted and fed state Compared with control subjects, glycerol appearance and lipid oxidation were significantly increased in NAFLD patients in the basal value, and were suppressed by insulin to a lesser extent. 44 Study data demonstrates that IR in skeletal muscle of young adults can promote atherogenic dyslipidemia by changing the pattern of ingested carbohydrates away from skeletal muscle glycogen synthesis into hepatic de novo lipogenesis. It leads to an increase in plasma TG and a reduction in high-density lipoprotein concentrations. 34 These changes are associated with abnormal serum ALT levels 42, 45 and fatty liver in adolescence. 32, 39 Research with rat model of hepatic steatosis showed that saturated fatty acids promote endoplasmic reticulum stress as well as hepatocyte injury. 46 In obese children, the susceptibility to NAFLD is associated with body fat distribution. Visceral fat is directly correlated with IR. Therefore, it is even more important than total fat mass in determining the risk of disease. [19] [20] [21] 29 Large scale study in the United States population has shown the association between high apoB/apoAI ratio and IR among 2955 adults. 47 This index also has a role in predicting the risk of fatty liver in adolescence. 48 Visceral adipose tissue, as an endocrine organ, is involved actively in the body metabolism. Increase in size and inflammation of fat cells during obesity could trigger some inflammatory and profibrotic process in liver.
Mitochondrial dysfunction
Mitochondrial dysfunction has shown principal role at several phases in pathophysiological process of steatohepatitis. The b-oxidation of fatty acids can be either increased (as in IR-associated NASH) or decreased (as in drug-induced NASH). However, in both circumstances, the damaged respiratory chain augments the generation of reactive oxygen species. 49, 50 In hepatocytes, reactive oxygen species and lipid peroxidation products further impair the respiratory chain, either directly or indirectly, through oxidative damage to the mitochondrial genome. 49 This, in turn, leads to the generation of more reactive oxygen species that results in a vicious cycle. Respiratory chain deficiency is responsible for apoptosis or necrosis and has a role in the pathophysiology of NASH independent of its initial cause. 5, 6, 50 Mitochondrial dysfunction has a key role in NASH. It is independent of IR and its consequences. Mitochondrial dysfunction facilitates fat accumulation and generation of reactive oxygen species that mediate necroinflammation and fibrosis in susceptible patients.
The 'two-hit' model Steatosis has shown a reversible process. The development of liver cell ballooning and inflammation (steatohepatitis) determines whether a patient progresses to irreversible liver damage and fibrosis. 51 This fact is the basis of 'two-hit theory' in which the first hit is an excessive hepatocyte TG accumulation resulting from IR. 52 The second hit involves an inflammatory injury to the liver. 51 The best candidates for these second hits were oxidative stress, associated lipid peroxidation and cytokines, principally tumor necrosis factor-alpha (TNF-a) or endotoxin, for example, as a response to pathogenic stimuli.
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Two-hit theory highlights some part of pathogenesis of fatty liver. It tries to explain why some cases of fatty liver have shown a progressive course. Further studies need to identify responsible factors. Results of these studies will facilitate screening of the high-risk group for NASH and developing prophylactic treatment for them.
Cytokines, adipokines and hormones
In the context of hepatic diseases, 'adipokines' (adipose tissue cytokines), which are uniquely expressed from visceral fat, directly target the liver through the portal vein. Ectopic fat represents a dysfunctional tissue more likely to undergo inflammation and to contribute to the pathogenesis of fatty liver. Mean plasma level of TNFa and interleukin-8 was significantly higher in NAFLD patients when compared with both obese versus nonobese controls than controls. 31, 54 Neutralization of TNFa in obese fa/fa rats caused a significant increase in the peripheral uptake of glucose in response to insulin. 55 Serum TNFa could be the independent predictor of fibrosis in NASH. 31 Adiponectin exerts insulin-sensitizing effects in the liver, skeletal muscle and adipose tissue. Administration of Pediatric nonalcoholic fatty liver K Widhalm and E Ghods adiponectin ameliorated liver necroinflammation and steatosis is partly through inhibition of TNFa. 56 Serum adiponectin is reduced in children, born small for gestational age, during critical period for growth (infancy, puberty). 6, 57 Depressed adiponectin has a more important role than elevated levels of circulating proinflammatory cytokines in elevated ALT and development of NAFLD in children. 58 There are increasing evidences about the direct connections between adipokines, cytokines and mechanism of hepatic damage and repair in fatty liver. Accordingly, these molecules are convincing for new screening biomarkers and development of novel therapies.
Nutrition-sedentary lifestyle
In most patients, overnutrition (excessive carbohydrate and fat intake) or inappropriate diet are thought to lead to chronically elevated glucose, insulin and free fatty acid concentrations in blood, independently or together. 42 These dietary conditions contribute to resistance to insulinstimulated glucose uptake in adipose tissue and skeletal muscle, as well as resistance to the insulin-mediated suppression of TG hydrolysis in adipose tissue. 42, 59 There is some evidence about the potential interaction of industrial toxins namely high-fructose corn syrup have a role in NASH, and there is increasing interest in the potential interaction of industrial toxins and nutrients. 42, [59] [60] [61] On the other hand, decreased physical activity in obese patients could promote IR 62 and fatty infiltration of the liver. 26, 37 Owing to the close relation to IR and obesity-related inflammation, dietary and lifestyle factors are thought to have a key role in pathogenesis of NAFLD. In addition, increased body mass index seems to correlate with long-term progression to fibrosis and cirrhosis.
Genetic predisposition A retrospective review of 90 patients observed over a 4-year period has shown that familial clustering of NAFLD was common with 18% of patients having a similarly affected first-degree relative. 63 Some of inherited MS(Prader-Willi, Angelman, Bardet-Biedl, Cohen, Alström, Börjeson-Forssman-Lehmann and Albright's hereditary osteodystrophy) have a genetic predisposition to pediatric NAFLD and NASH. 64 Fatty liver has been found in patients with congenital forms of lipodystrophy. Therefore, a common pathophysiological mechanism between these two diseases is possible. 65 Obesity and its comorbidity are categorized as the genetically complex diseases. The broad range of NAFLD phenotype found in individuals with similar metabolic characteristics points to a heterogeneous genetic contribution.
Obstructive sleep apnea
The available data suggests that sleep apnea-related hypoxia may alter glucose metabolism by promoting the release of inflammatory cytokines. 66 An animal study, modeling severe obstructive sleep apnea, showed that long-term exposure to hypoxia-reoxygenation resulted in the increase in fatty infiltration of the liver. This may exacerbate preexisting fatty liver in obesity through upregulation of the pathways of lipid biosynthesis in the liver. 67 Still in the absence of obesity, chronic intermittent hypoxia leads to mild elevated levels of liver enzymes, 68 liver injury by oxidative stress and excessive glycogen accumulation in hepatocytes and sensitizes the liver for a second injury. 69 It seems that sleep apnea is the leading cause of adverse metabolic outcomes. Although, further research need to conclude whether a cause and effect relationship exist. 66 In summary, most of the evidences supporting the pathophysiological mechanisms of fatty liver are projections from overlapping of potential mechanisms of obesity, IR and MS. On the other hand, it is not thoroughly clear why some of the cases have shown progressive course. Therefore, we could rely on the current coincidental manifestation of fatty liver to plan further studies improving sensitivity of diagnostic test and efficacy of therapeutic strategies.
Diagnosis
NAFLD in children is asymptomatic or with mild symptoms. 6, 26 Children may complain of abdominal pain. They often have hepatomegaly, although it may be missed in the physical examination. 29 Up to half of NASH cases had Acanthosis nigricans, as a cutaneous marker for hyperinsulinemia. 6, 26, 27 Fatty liver diagnosis occurs in as young as 2-year olds. Although, most of the diagnosis arises in the second decade of life. 26 Although an elevated ALT and an enlarged echogenic liver, revealed by ultrasonography, in the setting of overweight or obesity and/or evidence of IR is highly suggestive, but is not conclusive for NAFLD. 6, 13, 16, 20 Liver biopsy Liver biopsy is the ultimate standard for the diagnosis and semiquantitative analysis of injury in NASH. 1, 28 Liver biopsy is an expensive, invasive procedure and carries 0.06-0.35% risk of morbidity and 0.01-0.1% mortality, and is not feasible in a population-based study. 1 On the other hand, only a small fraction of fatty-liver patients show a progressive course. Combination of clinical tests, serum markers and imaging studies are appropriate for detecting the presence and severity of steatosis. 1, 6 New biomarker panels are coming closer to predict liver inflammation and fibrosis. It could prevent unnecessary liver biopsy. 7 Histopathology of NAFLD in an adult is defined in the classical way. The largest biopsy series of pediatric NAFLD represents two distinct injury patterns compatible with steatohepatitis. 28 The first pattern is consistent with NASH as described in adults denominated as 'type 1'. It is defined as the presence of steatosis with ballooning degeneration There is a correlation between clinical and pathological features of fatty liver. Clinical algorithmic approach can be used to identify the presence of fibrosis. They are appropriate for selection of high-risk group for performing liver biopsy. NASH subtypes and pathological score should be considered in planning studies and interpreting liver biopsies in the pediatric field.
Biochemical tests
Liver function test NAFLD is one of the most frequent reasons for liver function test elevation without clinical symptoms. But there are conflicting results to be able to use them as diagnostic criteria because of a wide range in specificity and sensitivity. 72 Some studies have shown the significance of transaminases in combination with age, gender, body mass index, central obesity and puberty for portend fatty liver. 16, 21, 26 Others have shown only the degree and duration of obesity (overweight to nonoverweight, 24-4%) associated with elevated liver enzymes. 22, 73 Serum insulin, TG, thyroidstimulating hormone, leptin, C-reactive protein (CRP) were significantly higher and the adiponectin level was lower in overweight children with elevated ALT-at risk group for fatty liver. 22, 29, 73 The controversial reports approved 'normal LFT' in obese children with radiological evidence of fatty liver 13 and in morbid obese patients undergoing bariatric surgery. 74 Retrospective reviews of liver biopsies have shown that NAFLD, with modest elevation of liver enzymes, is associated with a significant risk of developing end stage liver disease. 16, 28, 31 Another survey found some evidence of accompanying cardiovascular risks (metabolic syndrome) for live function test elevation to predict a severe fibrosis. 28, 37, 48, 75, 76 Therefore, usefulness of serum transaminase activities ratio was limited in predicting the severity of histological abnormality in NAFLD patients, 9, 16, 70, 77, 78 but not as diagnostic test of NAFLD, or in distinguishing NASH from NAFLD. 6, 29, 70 Research results insist on principle importance of IR tests in noninvasive criteria for diagnosis of fatty liver. Therefore, denying their contribution in screening and follow-up criteria is implausible. However, further studies need to identify the best criteria for IR among several tests. Exact cutoff point for standard reference is also needed.
Image studies
Primary imaging modalities for NAFLD are ultrasound and magnetic resonance imaging (MRI) with some technical limitations.
6,29 Measurement of visceral fat was a determinant factor to increase NAFLD prevalence in obese children. 23 Although, further investigations in imaging techniques for pediatric fatty liver needs to be performed. 6 No radiological modality detected the presence of hepatocyte ballooning, Mallory's hyaline or fibrosis, which are important features in the diagnosis of NASH. 86 Table 3 presents results of the imaging techniques used in diagnosis of NAFLD-NASH. 86, [90] [91] [92] [93] [94] [95] [96] [97] [98] [99] [100] [101] [102] [103] [104] [105] [106] [107] [108] [109] The underlying physical principle of imaging techniques are the same between adults and children. Consequently research in both age groups could be used to approve the use of these methods in pediatric field. Pediatric Abbreviations: APRI score, AST to platelet ratio index; GGT, g-glutamyl-transpeptidase; HOMA-IR, homeostasis model assessment insulin resistance; QUIKI, quantitative insulin sensitivity check index; Sen, sensitivity; Spe, specificity; WBISI, whole body insulin sensitivity index; HOMA-IR: (fasting insulin (mU/l) Â fasting glucose (mmol/l)/22.5). QUICKI: À1/log (glucose (mg per 100ml) Â insulin (mU/l)). WBISI: 10 000/[((fasting insulin Â fasting glucose) Â (mean glucose Â mean insulin)).
a Accuracy of diagnostic test or criteria determined by calculation of area under the receiver operating curve (AUC) or Odds Ratio (OR). b Predictability of test identified by positive negative predicting value (PPV-NPV) and P-value. /l)À0.66 Â albumin (g per 100 ml).
h PNFI ¼ 1/1+e Àip Â 10 (ip ¼ À Â +6.539 log e (age (years)) 0.207 Â waist circumference (cm)+1.957 Â log e (triglycerides (mg per 100ml))À10.074). i a2-macroglobulin; apo A1, haptoglobin, GGT and total bilirubin for liver fibrosis measurement (FibroTest)+ALT for liver activity (ActiTest). 
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Ultrasonography (US)
Hepatic steatosis appears as a diffuse increase in echogenicity due to the increased parenchymal reflectivity caused by intracellular accumulation of fat inclusions. 86 NAFLD is defined when fatty infiltration exceeds 5% of hepatocytes. 14 In adults, the technique of ultrasound has a sensitivity of 60-94% and a specificity of 73-93% for the diagnosis of fatty liver, whereby the accuracy of US in children has not been established. 6, 23, [86] [87] [88] Hamaguchi et al. compared US score between 94 biopsy-proven fatty liver patients and 4826 participants who were selected from the general population. This study supports the applicability of abdominal US as a screening examination. The specificity of this method could be increased up to 100% if known liver disease, drug use or alcohol consumption were ruled out. 89, 90 However, US could not detect 7.4-8.8% of cases with NAFLD. However, the presence of fibrosis is not related to misdiagnosis. In addition, it is possible to differentiate fibrosisFespecially severe degreeFfrom steatosis. 86, [88] [89] [90] Visceral fat measured by ultrasound might be a good predictor to identify risk for nonalcoholic fatty liver disease in obese adolescents. 21, 23, 89, 90 Liver involvement assessed by means of US is as frequent as 42% among prepubertal children 6, higher than that revealed by measurement of serum liver enzymes. 13 Doppler sonography is used as noninvasive assessment of the hemodynamics of hepatic vascular flow. Investigation based on this technique has shown lower vascular compliance in the portal vein in NAFLD than in controls. 91 The hepatic and portal vein flow pattern is correlated with fatty infiltration, and occasionally with inflammation and fibrosis. 13, 92, 93 US of the liver is a safe and repeatable imaging technique. It should be part of the routine health examination of obese adolescents. In addition, it could be used for follow up of treatment in different intervals. Nevertheless, we must consider its limitation in exact quantification of fat accumulation, differentiating fibrosis from steatosis and reproducibility.
Computed tomography (CT scan)
Hepatic steatosis is best visible in nonenhanced CT images and presents with decreased attenuation values of the parenchyma. 87 Measurement of attenuation values, the difference in attenuation values between liver and spleen, as well as the calculation of the spleen-to-liver attenuation ratio used for assessment of hepatic steatosis. 88, 92 CT attenuation values correlated to a certain degree of hepatic steatosis measured by biopsy. 91 Although, it can detect hepatic fat content, but only at a threshold of 30% infiltration. [93] [94] [95] Consequently, CT is not clinically acceptable for diagnosis of mild to moderate hepatic steatosis. 87, 96 CT is associated with radiation exposure which limits its use for longitudinal studies and in children.
Magnetic resonance imaging
The physical basis of this procedure is based on difference of resonance frequencies between hydrogen protons bound to Superparamagnetic iron oxide-enhanced MRI may be helpful for identifying NASH patients among patients suspected of having NAFLD by decreasing the signal from the nonfibrotic areas where Kupffer cells are present. 99 Magnetic resonance spectroscopy is probably the most accurate and fastest method of detecting fatty infiltration, but it is expensive, and the necessary software is still not easily available in most MRI units. 6, 87 The prevalence of hepatic steatosis in 2349
participants from the Dallas Heart Study was estimated to be 33.6% and correlated well with pathological finding.
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1H magnetic resonance spectroscopy of the liver has emerged to be a fast, safe and noninvasive alternative for the quantification of hepatic fat content. 87 13C nuclear magnetic resonance spectroscopy also has shown consistent results compared with blinded liver biopsy. 101 Liver stiffness measurement by transient elastography is a reliable method for predicting significant liver fibrosis. [102] [103] [104] [105] [106] [107] [108] Discordance of transient elastography with liver pathology may be related to unsatisfactory liver biopsy specimen.
101
Magnetic resonance offers imaging and spectroscopic methods for quantification of fat with relatively high accuracy without any invasive procedures or radiation exposure. It seems that MR method could be helpful to obtain quantitative data of lipid content in liver. Follow-up studies are also facilitated by applying MR-based techniques.
Biomarkers
Cytokines-adipokines-oxidative stress by-products On the basis of the 'two-hit' theory, hepatocyte steatosis is a prerequisite for the subsequent events that lead to liver injury and fibrogenesis. Mitochondrial dysfunction is thought to have a central role in the progression from steatosis to NASH. 109 Three groups of biomarkers were assessed for correlation with liver injury: Table 2 represents the research results about the role of this group in predicting NASH. Nonalcoholic steatohepatitis is associated with increased oxidant capacity, especially in the presence of liver fibrosis. 49, 110, 111 Multiple by-products of oxidative stress have been measured and some of these markers may be useful as a diagnostic tool for NAFLD. 109, 112 Significant decrease occur in hepatic P450 activity during progressive stages of NAFLD. 111 Increased expression of proinflammatory cytokines such as TNFa and interleukin1b was may be responsible for observed decreases in respective P-450 activity. [113] [114] [115] [116] [117] Original European Liver Fibrosis study used age, tissue inhibitor of matrix metalloproteinase 1, hyaluronic acid, amino-terminal peptide of procollagen III for detection of fibrosis in fatty liver. In contrast, pathologists' agreement over histological scores ranged from very good to moderate (k ¼ 0.97-0.46). 117, 118 The clinical utility model by removing age showed that 82% of liver biopsies could be potentially avoided for the diagnosis of severe fibrosis. This criteria was validated in pediatric NAFLD. 118 Yoneda et al. 82 have published the first report to demonstrate consistent and profound elevation of high-sensitivity CRP in cases of NASH compared with simple steatosis. The high-sensitivity CRP is superior to anthropometric parameters as a marker of the metabolic consequences of obesity. 119, 120 It could not only distinguish NASH from simple nonprogressive steatosis but also indicate the severity of hepatic fibrosis in NASH. [121] [122] [123] [124] [125] [126] [127] [128] [129] High-sensitivity CRP, circulating TNF-a, interleukin-6 and cytokine-18 levels are significantly increased in NASH compared with simple steatosis and healthy volunteers. 111, 122, 123 Hypoadiponectinemia in NAFLD is part of a metabolic disturbance characterized by decreased hepatic insulin sensitivity and by increased ectopic fat accumulation in the central compartment, especially in the liver. 82 Recently, a rabbit model producing the key features of pediatric NASH concluded that adiponectin levels partially reflect the severity of liver steatosis, but not the degree of liver inflammation.
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Systemic inflammatory substances and adipocytokines are of key importance in pathogenesis of NASH. Therefore, measurement of these biomarkers should be part of the standard evaluation of the obese child and may help to evaluate the occurrence of NAFLD and could predict progressive form of disease. However, there will be potential for developing novel therapies for NASH. Table 4 summarizes research results on noninvasive tests or criteria for diagnosis and follow-up of NAFLD-NASH. The probable ratio for NASH is between 2.15 and 28.6 for positive and between 0.06 and 0.48 for negative likelihood ratio. The prevalence (pretest odds or the probability of the disease state before test) of NASH has a range from 10 to77% overall and even 87% in obese children. 10, 13, 19, 70 The post test odds (pretest odds Â likelihood ratio) for a positive test (presence Pediatric nonalcoholic fatty liver K Widhalm and E Ghods of fibrosis) are a minimum of 53.35% and for a negative test are 4.85% (blue font). Consequently, unnecessary invasive test (liver biopsy) could be prevented at least in about half of the cases. Figure 1 shows the flowchart diagram for 'diagnosis of nonalcoholic fatty liver'. Routine biochemical test, including liver transaminases and liver US, result in four different groups. In cases with elevated liver enzymes, other causes of chronic liver disease (viral hepatitis, a 1 antitrypsin deficiency, Wilson's disease and so on) must be ruled out. MRI (standard MRI or MRS) could quantify fat content of the liver more precisely and approve NAFLD in high-risk patient with normal transaminase level and/ or normal US, but with clinical symptom of liver involvement. The second step is checking the presence of IR whether any of the tests above are suggestive of fatty liver. Lipid profile (high-density lipoprotein, apoB/apoA1 and TG) and cardiorespiratory fitness test (measuring peak oxygen uptake during a maximal exercise test) perform to show the metabolic risk of liver involvement. In the next step, inflammatory biomarkers (adipocytokines, TNFa, high-sensitive CRP, cytokine-18, hyaluronic acid) or transient elastography carry out to determine any fibrosis or progress course of fibrosis in target group. Consequently, the liver biopsy (invasive test) should be performed in patients highly suspicious to NASH on the basis of organized decision scheme. This chart could be used for follow up. In this case, focus will be with regard to proposed changes based on treatment strategy.
Treatment
NAFLD, especially with elevated liver enzymes, may develop fibrosis and progress to end stage liver disease. Therefore, it should be treated as early as possible. 5, 13 The treatment strategies of NASH are on the basis of the current best understanding of the pathophysiology of this disease, the so-called two-hit theory'. 51 These approaches, explored in therapy for both adult and pediatric NASH, include (1) diagnosis and treatment of related metabolic disturbances such as diabetes and hyperlipidaemia (2) targeting IR by weight loss (healthy lifestyle: diet and exercise) or pharmacotherapy and (3) control of the secondary processes promoting to oxidative stress, inflammation, apoptosis and hepatic fibrosis by using hepatoprotective agents such as antioxidants. 6, 26, [130] [131] [132] [133] [134] [135] [136] [137] [138] [139] However, it is important to exclude secondary causes for hepatic steatosis. Treatment in these cases differs and revolves around correcting the underlying cause. 130 Table 5 has shown the list of pharmacological agents attributed to the treatment of NAFLD-NASH. [131] [132] [133] [134] [135] [136] [137] [138] [139] [140] [141] [142] [143] [144] [145] [146] [147] Only metformin 135 and vitamin E 140 have been used until now in clinical trials, but there is some evidence because of efficacy in adult and safety in children for other groups such as antiobesity (orlistat), 129, 131 angiotensin-converting enzyme inhibitor 132 and stations. 133, 138 These evidences in parallel to other novel therapies [141] [142] [143] [144] [145] [146] [147] must be considered in designing future clinical trials for treatment of pediatric fatty liver.
Weight loss
Given the strong association between obesity, IR and NAFLD, weight loss through dietary advice and increased physical activity seems to be an appropriate way of management or even preventative strategy for NAFLD in children and adolescence. 20, 33, 48, 138, 144, 145 As underdiagnosis of pediatric obesity commonly occurs, the opportunity for screening for NAFLD is lost. 148 Lifestyle modification and dietary advice with a very modest 53, 127 or even no-weight reduction 6, 33, 42 can result in changes in body fat depots and improvements in liver function test, 140,144 cytokines 83, 109 and histology in NASH. 33, 140, 149 There are some in vitro studies or small trials on the effect of ketogenic, hypoenergetic diet, 144, 145 specific diets rich in omega-3 polyunsaturated fatty acids 42, 138, [149] [150] [151] or a short-chain oligofructose-enriched diet 42, 152 that have shown improvement in liver enzyme and pathology in NAFLD patients. Muscle contraction because of exercise induces glucose transporter-4 translocation factors, decreases fatty acid and TG accumulation in the myocytes, and increases insulin sensitivity. 153 The degree of improvement in insulin sensitivity is related to the intensity and duration of the exercise. 154 Although isolated physical activity has not shown to be effective for weight loss or obesity-associated dyslipidemia, appropriate levels of physical activity can alter body composition and contribute to weight maintenance. 153 Overall, the longer the physical activity the greater the effect is on body weight and central obesity. 154 On the basis of short-term randomized trials, an aerobic exercise prescription of 155-180 min/week at moderate-to-high intensity is Likelihood ratios are used for assessing the value of performing a diagnostic test. They use the sensitivity and specificity of the test to determine whether a test result usefully changes the probability that a condition (such as a disease state) exists.
Pediatric nonalcoholic fatty liver K Widhalm and E Ghods effective for reducing body fat in overweight children, not on body weight and central obesity. 154, 155 Lots of research has shown comparable short 144, 151 and longterm effects on weight reduction 140, 149 in treatment of fatty liver to many other medical and surgical modalities. 148, 156, 157 Lifestyle interventions delineate the first step in the management of children with NAFLD. However, the longterm impact of the treatment on the disease course remains unclear. In addition, therapies based on lifestyle modification alone are notably hard to sustain, especially in adolescence. There is a need to randomize controlled trials with a careful proceeding plan in this area.
Weight-loss surgery
Bariatric surgery is the mainstay of NAFLD therapy in morbidly obese subjects. 6, 7, 26, 42, 157, 158 Resolution of obesity-related comorbidities has been shown in majority of adolescents undergoing surgery. 157 Those with a MS had more improvement with surgical weight loss. However, a very rapid weight loss, may lead to aggravation of inflammation, fibrosis and steatosis in rare cases. 134 Initial and follow-up biopsy in bariatric surgery patients have shown major improvements in all pathological features at the second biopsy, except for portal abnormalities. 
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Roux-en-Y gastric bypass led to substantial weight reduction. Short-term follow-up after a bypass has shown improvement in all of the pathological findings of NAFLD, despite the severity at baseline. 157, 160 Long-term randomized control studies are required to determine possible changes in the portal regions or relapse of NASH that could tend to weight regain or malnutrition. 160 There are some data obtained because of the effect of metformin in improving IR, as well as, biochemical and histological markers of NASH. 7, 135, 150 The Treatment of Nonalcoholic Fatty Liver Disease in Children (TONIC) trial is ongoing. Nondiabetic boys and girls, aged 8-15 years, with biopsy-proven NAFLD from nine states in the USA, receive vitamin E, metformin or placebo for 2 years. TONIC results could be used in improving treatment strategies, thereafter. 161 Behavioral interventions are especially difficult among adolescence. Therefore, additional therapies to improve liver health are urgently needed in this high-risk population. Metformin increases insulin sensitivity with or without NAFLD. 37 However, further studies are needed to determine the extent of disease in adolescents and the best treatment strategy to decrease the risk of progression to fibrosis and cirrhosis. 37, 162 Approximately one-half of obese children had serum levels of a-carotene and a-tocopherol in the lowest quartile compared with approximately one-quarter of normal weight children. 163 Daily oral vitamin E administration normalized Aquaporins are a family of water-specific, membrane-channel proteins, selectively conduct water molecules in and out of the cell such as glycerol.
b Betaine is a metabolite of choline that assists with the synthesis of S-adenosylmethionine.
c Pentoxifylline is a methylxanthine compound known to inhibit the production of TNFa. m, increase; k, decrease. Pediatric nonalcoholic fatty liver K Widhalm and E Ghods serum aminotransferase and alkaline phosphatase levels in children with NASH. Oral vitamin E warrants consideration in obesity-related liver dysfunction for children unable to adhere to low-calorie diets. 162, 164 Some studies failed to find a significant effect of vitamin E on transaminases, hepatic inflammation and fibrosis. The improvement in steatosis and cytological ballooning is related to treatment-associated decreases in fasting free fatty acid and insulin levels. 138, 140, 162 In most cases, cytokines plasma level generally did not decrease significantly with weight loss even by supplementary treatment with vitamin E. 140, 144, 149, 151 In addition, long term high dose vitamin E supplementation (4400 IUday) has been associated with increased all-cause mortality and should be avoided. 165 Table 6 has shown the details about the clinical studies in pediatric NAFLD treatment. 33, The therapeutic arena for NAFLD addressed the features of the MS, including diabetes, obesity and dyslipidemia. There is some evidence of improving IR or decreasing inflammatory mediators to prevent or slow the development of NASH. Up to now there are limited data to conclude leading drug candidates, although there are several promising concepts in drug development. Large, multicenter studies of insulinsensitizing and antioxidant therapy (TONIC) are under way. On the other hand, dietary patterns of children with NAFLD should be characterized. In parallel to the evaluation of the role of diet in disease expression, there should be a special concentration on availability of essential nutrients for the growth spurts in infancy and puberty. Bariatric surgery is becoming a principal treatment modality for morbid obesity, but maintenance of weight control will require dieting and exercise. Therefore, optimal lifestyle interventions in pediatric NAFLD are yet to be defined.
